Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14251 - 14275 of 14855 in total
Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
Investigational
Izokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).
Investigational
Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).
Investigational
Sotevtamab is under investigation in clinical trial NCT06225843 (Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis).
Investigational
Investigational
Ovemotide is under investigation in clinical trial NCT00357461 (Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma).
Investigational
Hepcidin-25 is under investigation in clinical trial NCT03381833 (A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-dependent Beta Thalassemia).
Investigational
Quaratusugene ozeplasmid is under investigation in clinical trial NCT05062980 (Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-small Lung Cancer).
Investigational
Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy) for the treatment of Recurrent Head/Neck Cancer.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
CDX-301 is under investigation in clinical trial NCT02129075 (A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma).
Investigational
Investigational
Developed by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]
Investigational
Investigational
BA1301 is an anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5.
Investigational
AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131...
Investigational
Matched Description: … is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and
Displaying drugs 14251 - 14275 of 14855 in total